News

OXi4503, which has shown significant activity in preclinical studies of AML, is a novel VDA that is designed to reduce blood flow to tumors and to prevent cancer

Results were presented today in a poster presentation during the 15th European AIDS Conference, which is hosted by the European AIDS Clinical Society (EACS) and being held October

The Swiss pharma firm has also signed licensing agreements with drug developers Palobiofarma and XOMA. The transactions add Admune’s IL-15 agonist program, Palobiofarma’s PBF-509 adenosine receptor and Xoma’s

Clarient, which employees about 415 people, booked $127m in revenues and $13M in EBITDA in 2014. Clarient Diagnostic Services offers a range of cancer diagnostic testing services to

The parties were unable to reach an agreement on the modification of the financial terms of the agreement and on development strategy in Japan, in light of the

The trial showed statistical significance that the product provided pain relief after surgery in the treatment group using ELI-200 compared to the placebo group. The company said secondary

Results from the randomised, blinded study 201316 showed that umeclidinium 62.5mcg once daily achieved a statistically significant improvement in lung function measured by trough forced expiratory volume in

Until today’s orphan drug approval, no specific coagulation factor replacement therapy was available for patients with hereditary Factor X deficiency. In healthy individuals, the Factor X protein activates

As on June 30, 2015, Jubilant Life Sciences had a total of 815 filings for formulations of which 389 have been approved in various regions globally. This includes